SCHEMBL2540966

SCHEMBL2540966

CC(C)(C)c1ccc(COc2ccc(-c3ccccc3)cc2C=CC(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 7/20 0.53
PTGER2 P43116 7/20 0.53
PTGER3 P43115 7/20 0.53
PTGER1 P34995 4/20 0.53
PSEN1 P49768 2/20 0.53
ALOX5 P09917 1/20 0.53
LTB4R Q15722 1/20 0.53
LTB4R2 Q9NPC1 1/20 0.53
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
XDH P47989 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
TNFRSF1A P19438 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540962 1.00 PTGER4 (0.53) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2541531 0.97 PTGER4 (0.57) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2541533 0.97 PTGER4 (0.57) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2541460 0.97 PTGER4 (0.51) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2541463 0.97 PTGER4 (0.51) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2535065 0.92 PTGER4 (0.55) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2535063 0.92 PTGER4 (0.55) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2540423 0.91 PPARG (0.51) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2541455 0.91 PSEN1 (0.56) PTGER4PTGER2PTGER3PTGER1PSEN1
SCHEMBL2533731 0.91 RXRA (0.49) PTGER4PTGER2PTGER3PTGER1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 PTGER4 3046/4885PTGER2 2944/4885PTGER3 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.